Last year saw an end-to-end meeting, bringing together an exclusive forum of leaders within R&D, CMC, manufacturing, supply chain, process development and analytics that are working to define gold standard approaches for donor characterization, testing and cell source procurement for safe and globally accessible off-the-shelf cell therapies.Â
What Can You Expect?
3
days of unmissable content covering key challenges from R&D, CMC, manufacturing, supply chain, process development and analytics
2
revitalized workshop sessions to take part in intimate discussions with KOLs from Poseida Therapeutics and CytoImmune Therapeutics
20+
hours of dedicated sessions covering the end-to-end scope of donor selection, screening, characterizing and making critical decisions to guarantee commercialization and marketing access
Must-Attend Sessions
Who's Attending?
I felt that this was a very unique meeting where suppliers and consumers of blood products finally got in the same room to talk about the challenges and potential solutions to creating stable sources of apheresis units for allogeneic products
Senior Director - Chemistry, Manufacturing & Controls, Regulatory Affairs, Imugene - 2023 Attendee